B-FREE Chronic Babesiosis Study
← catalyst calendarNCT06656351 · readout ≤ 193 d
Sponsored by 60 Degrees Pharmaceuticals LLC (industry) · SXTP — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
40estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-18 | actual | When the study began enrolling |
| Primary completion | Feb 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Babesiosis
Intervention
- Drug: Tafenoquine 100mg
Primary outcome
what the primary-completion date above is the date OFChange in General Fatigue
measured From enrollment until Day 90 of treatment.
Permalink · SXTP's whole pipeline · Catalyst calendar · Every registered study · What changed